INOVIQ Ltd (ASX:IIQ)
Mary Harney serves as a Non-Executive Director at INOVIQ Ltd since October 2024 and holds the position of Chair at Oncology One Pty Ltd since May 2020. Mary Harney is the Executive Director of Mary Harney Advisory, established in February 2019, and previously chaired Microbio from February 2023 to October 2024, as well as Race Oncology from February 2021 to September 2024. In 2021, Mary Harney acted as the Interim Chief Executive Officer at Breakthrough Victoria, focusing on sustainable business development. Other roles include serving as Executive Director (acting) for Global Health Alliance Australia and providing strategic advice to the Australian Psychological Society and the Australian Organics Recycling Association. Mary Harney was the Chief Executive Officer of the Royal Australasian College of Surgeons from October 2017 to March 2019. Educational qualifications include advanced programs at INSEAD, a Graduate Certificate from the Australian Institute of Company Directors, a Bachelor of Arts from the University of Melbourne, and a Bachelor of Science from Monash University, among others.
This person is not in the org chart
This person is not in any teams
INOVIQ Ltd (ASX:IIQ)
INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours.